| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/16/2009 | US20090182058 Novel Chalcone Derivatives With Antimitotic Activity |
| 07/16/2009 | US20090182043 Pharmaceutical Preparation of Aqueous Solution Containing Platinum Complex |
| 07/16/2009 | US20090182042 Tiglien-3-one derivatives |
| 07/16/2009 | US20090182038 Leptomycin Derivatives |
| 07/16/2009 | US20090182029 2-indolinone derivatives as selective histone deacetylase inhibitors |
| 07/16/2009 | US20090182028 Plant Components and Extracts and Uses Thereof |
| 07/16/2009 | US20090182027 Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| 07/16/2009 | US20090182019 Histone deacetylase inhibitors |
| 07/16/2009 | US20090182003 Methods and Compositions for Treatment Cell Proliferative Disorders |
| 07/16/2009 | US20090182002 Tyrosine kinase inhibitors |
| 07/16/2009 | US20090182001 Inhibitors of checkpoint kinases |
| 07/16/2009 | US20090181990 Stable amorphous form of pemetrexed disodium |
| 07/16/2009 | US20090181989 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer |
| 07/16/2009 | US20090181988 Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof |
| 07/16/2009 | US20090181985 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND |
| 07/16/2009 | US20090181982 Substituted pyrroline kinase inhibitors |
| 07/16/2009 | US20090181973 Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas |
| 07/16/2009 | US20090181972 Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications |
| 07/16/2009 | US20090181971 Inhibitors of Histone Deacetylase |
| 07/16/2009 | US20090181970 Functionalized diarylisoxazoles inhibitors of ciclooxygenase |
| 07/16/2009 | US20090181964 Propane-1,3-Dione Derivative or Salt Thereof |
| 07/16/2009 | US20090181963 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| 07/16/2009 | US20090181960 17BetaHSD TYPE 5 INHIBITOR |
| 07/16/2009 | US20090181957 Benzimidazolone derivatives as cb2 receptor ligands |
| 07/16/2009 | US20090181951 Parp inhibitors |
| 07/16/2009 | US20090181949 1h-imidazole derivative having cb1, agonistic, cb1 partial agonistic or cb1 antagnistic activity |
| 07/16/2009 | US20090181944 Method for cancer therapy |
| 07/16/2009 | US20090181943 Inhibitors of Histone Deacetylase |
| 07/16/2009 | US20090181938 Aminopyrimidines useful as kinase inhibitors |
| 07/16/2009 | US20090181932 COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS |
| 07/16/2009 | US20090181913 SPECIFIC GRP78 EXPRESSION-INHIBITION RNAi SEQUENCE, MEDICINE THEREOF AND METHOD THEREOF |
| 07/16/2009 | US20090181907 Drug Comprising As The Active Ingredient Proliferative Vector Containing Survivin Promoter |
| 07/16/2009 | US20090181897 Cxcr4 antagonist and use thereof |
| 07/16/2009 | US20090181894 Chimeric toxins for targeted therapy |
| 07/16/2009 | US20090181891 Exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers; used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization. |
| 07/16/2009 | US20090181110 Compositions from Garcinia as Aromatase Inhibitors for Breast Cancer Chemoprevention and Chemotherapy |
| 07/16/2009 | US20090181100 Dry powder aerosols of Nanoparticulate drugs |
| 07/16/2009 | US20090181095 Oxidative stress inhibitor |
| 07/16/2009 | US20090181091 Product and process to regulate a gene network involved in constitutive inflammation and early cancer progression |
| 07/16/2009 | US20090181090 Protein-Based Carrier System for Overcoming Resistance in Tumour Cells |
| 07/16/2009 | US20090181088 Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof |
| 07/16/2009 | US20090181081 Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance |
| 07/16/2009 | US20090181035 Plexind1 agonists and their use |
| 07/16/2009 | US20090181034 Antibodies and related molecules that bind to psca proteins |
| 07/16/2009 | US20090181032 facilitate drug delivery of other molecules; e.g. use intraocularly in eye surgery, glaucoma, retinopathy treatments |
| 07/16/2009 | US20090181030 Use of a preparation based on an antibody directed against a tumor-associated glycosylation |
| 07/16/2009 | US20090181029 Methods for treating interleukin-6 related diseases |
| 07/16/2009 | US20090181022 Bispecific binding agents for modulating biological activity |
| 07/16/2009 | US20090181021 Ctsp Cancer-Testis Antigens |
| 07/16/2009 | US20090181016 FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| 07/16/2009 | US20090181014 Compositions and methods for the diagnosis and treatment of tumor |
| 07/16/2009 | US20090181013 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 07/16/2009 | US20090180996 Epigenetic modification of cell phenotype, fate and/or function by RNA transfer |
| 07/16/2009 | US20090180994 Oncolytic virus therapy |
| 07/16/2009 | US20090180988 Id-1 and Id-2 Genes and Products as Therapeutic Targets for Treatment of Breast Cancer and Other Types of Carcinoma |
| 07/16/2009 | US20090180984 Macrocyclic oximyl hepatitis c serine protease inhibitors |
| 07/16/2009 | US20090180953 Invention concerning GLP-1 and exendin |
| 07/16/2009 | US20090180952 Ligands binding the complex of urokinase-type plasminogen activator (uppa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy |
| 07/16/2009 | DE102008004100A1 New metallocene compounds are estrogen receptor modulators useful e.g. to treat preferably cancer, manic disorder, gynecomastia and/or female infertility, and to prevent mamma carcinoma |
| 07/16/2009 | CA2714888A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 07/16/2009 | CA2711803A1 Pyridine derivatives |
| 07/16/2009 | CA2711782A1 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| 07/16/2009 | CA2711741A1 Pyrazolopyridines as kinase inhibitors |
| 07/16/2009 | CA2711734A1 Method and compositions for administering resveratrol and pterostilbene |
| 07/16/2009 | CA2711699A1 Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 07/16/2009 | CA2711692A1 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| 07/16/2009 | CA2711691A1 Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same |
| 07/16/2009 | CA2711678A1 Inhibitors of carbonic anhydrase ix |
| 07/16/2009 | CA2711652A1 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | CA2711614A1 Pyrrolopyridines as kinase inhibitors |
| 07/16/2009 | CA2711611A1 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy |
| 07/16/2009 | CA2711606A1 Inhibitors of iap |
| 07/16/2009 | CA2711557A1 Anti-cldn6 antibody |
| 07/16/2009 | CA2711491A1 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide |
| 07/16/2009 | CA2711434A1 Epoxy-guaiane derivatives and treatment of cancer |
| 07/16/2009 | CA2711221A1 Triarylmethane analogs and their use in treating cancers |
| 07/16/2009 | CA2711029A1 Anti mif antibodies |
| 07/16/2009 | CA2710913A1 Use of a gamma-secretase inhibitor for treating cancer |
| 07/16/2009 | CA2710841A1 Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof |
| 07/16/2009 | CA2702791A1 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particularas c-met inhibitors |
| 07/15/2009 | EP2078731A1 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| 07/15/2009 | EP2078712A1 Indole derivatives as selective androgen receptor modulators (sarms) |
| 07/15/2009 | EP2078531A2 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 07/15/2009 | EP2078528A1 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 07/15/2009 | EP2078082A1 Recombinant human interferon-like proteins |
| 07/15/2009 | EP2078027A1 Cathepsin proteases inhibitors |
| 07/15/2009 | EP2078021A2 Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| 07/15/2009 | EP2078020A1 Fused ring heterocycle kinase modulators |
| 07/15/2009 | EP2078019A2 Purines as pkc-theta inhibitors |
| 07/15/2009 | EP2078018A1 Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| 07/15/2009 | EP2078016A2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| 07/15/2009 | EP2078012A2 Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| 07/15/2009 | EP2078010A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 07/15/2009 | EP2078009A1 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
| 07/15/2009 | EP2078004A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| 07/15/2009 | EP2078003A1 Anilinopiperazine derivatives and methods of use thereof |
| 07/15/2009 | EP2078002A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| 07/15/2009 | EP2077855A1 Therapeutic use of gba2 |
| 07/15/2009 | EP2077845A2 Macrocyclic quinazoline derivatives as vegfr3 inhibitors |
| 07/15/2009 | EP2077843A1 Use of a mt kinase inhibitor for treating or preventing brain cancer |